Alpha 2.0
Login Register
» Authors » Deliana Kostova

Deliana Kostova

Explore the profile of Deliana Kostova including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 627
Followers 0
Related Specialties
Public Health
General Medicine
Health Services
Top 10 Co-Authors
Muhammad Jami Husain
Patricia Richter
Rachel Nugent
Biplab Kumar Datta
Andrew E Moran
Samira Asma
Frank J Chaloupka
Brian Hutchinson
Ayda Yurekli
Hana Ross
Published In
Nicotine Tob Res
Tob Control
PLoS One
BMJ Open
Prev Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Cost analysis of adding hypertension and diabetes management into routine HIV care in Mbarara and Ibanda districts, Uganda
Ninsiima M, Basu S, Husain M, Kawungezi P, Kabami Z, Nakafeero Simbwa B, et al.
BMC Health Serv Res . 2024 Nov; 24(1):1392. PMID: 39538306
Background: In 2016, Uganda introduced services for hypertension and diabetes in selected HIV clinics. We evaluated the costs associated with scaling up these services in HIV clinics in Mbarara and...
2.
Comparing scale up of status quo hypertension care against dual combination therapy as separate pills or single pill combinations: an economic evaluation in 24 low- and middle-income countries
Hutchinson B, Husain M, Nugent R, Kostova D
EClinicalMedicine . 2024 Sep; 75:102778. PMID: 39281100
Background: International hypertension treatment guidelines recommend initiating pharmacological treatment with combination therapy and using fixed dose single pill combinations (SPCs) to improve adherence. However, few countries have adopted combination therapy...
3.
Scaling hypertension treatment in 24 low-income and middle-income countries: economic evaluation of treatment decisions at three blood pressure cut-points
Hutchinson B, Walter A, Campbell N, Whelton P, Varghese C, Husain M, et al.
BMJ Open . 2024 Apr; 14(4):e071036. PMID: 38626959
Objective: Estimate the incremental costs and benefits of scaling up hypertension care in adults in 24 select countries, using three different systolic blood pressure (SBP) treatment cut-off points-≥140, ≥150 and...
4.
Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries
Li C, Spencer G, Husain M, Nugent R, Auzenne D, Kostova D, et al.
PLOS Glob Public Health . 2024 Feb; 4(2):e0002905. PMID: 38346061
Despite the high burden of hyperlipidemia and the effectiveness of treatment, evidence suggests that the accessibility of hyperlipidemia medicines can be low in many low- and middle-income countries (LMICs). The...
5.
Cost analysis of the WHO-HEARTS program for hypertension control and CVD prevention in primary health facilities in Ethiopia
Alemayehu Beshah S, Husain M, Dessie G, Worku A, Negeri M, Banigbe B, et al.
Public Health Pract (Oxf) . 2023 Sep; 6:100423. PMID: 37727705
Background: In 2020, Ethiopia launched the Ethiopia Hypertension Control Initiative (EHCI) program to improve hypertension care using the approach described in the WHO HEARTS technical package. Objective: To estimate the...
6.
The HEARTS partner forum-supporting implementation of HEARTS to treat and control hypertension
Khan T, Moran A, Perel P, Whelton P, Brainin M, Feigin V, et al.
Front Public Health . 2023 Aug; 11:1146441. PMID: 37554732
Cardiovascular diseases (CVD), principally ischemic heart disease (IHD) and stroke, are the leading causes of death (18. 6 million deaths annually) and disability (393 million disability-adjusted life-years lost annually), worldwide....
7.
Assessing costs of a hypertension program in primary care: evidence from the HEARTS program in Mexico
Chivardi C, Hutchinson B, Molina V, Moreno E, Fajardo I, Giraldo-Arcila G, et al.
Rev Panam Salud Publica . 2022 Sep; 46:e144. PMID: 36128473
Objective: In 2021, Mexico launched the HEARTS program to improve the prevention and control of cardiovascular disease (CVD) risk factors in 20 primary care facilities in the states of Chiapas...
8.
Cost assessment of a program for laboratory testing of plasma trans-fatty acids in Thailand
Datta B, Aekplakorn W, Chittamma A, Meemeaw P, Vesper H, Kuiper H, et al.
Public Health Pract (Oxf) . 2022 Sep; 2:100199. PMID: 36101632
Objectives: Intake of trans fatty acids (TFA) increases the risk of cardiovascular disease. Assessment of TFA exposure in the population is key for determining TFA burden and monitoring change over...
9.
Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries
Moran A, Farrell M, Cazabon D, Sahoo S, Mugrditchian D, Pidugu A, et al.
Rev Panam Salud Publica . 2022 Sep; 46:e140. PMID: 36071923
Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated...
10.
The Case for Integrating Health Systems to Manage Noncommunicable and Infectious Diseases in Low- and Middle-Income Countries: Lessons Learned From Zambia
Richter P, Aslam M, Kostova D, Lasu A, Vliet G, Courtney L, et al.
Health Secur . 2022 Jul; 20(4):286-297. PMID: 35904943
Noncommunicable diseases (NCDs) are the leading cause of death in the world, and 80% of all NCD deaths occur in low- and middle-income countries (LMICs). The COVID-19 pandemic has demonstrated...